About FANGZHOU JIANKE Company

According to Insight Consulting, we are the largest online chronic disease management platform in China with an average monthly active user count in 2023. Our business focuses on chronic disease management to meet the needs of patients with chronic diseases such as hypertension and chronic cardiovascular and respiratory diseases. In response to the needs of patients with chronic diseases for convenient and popular medical services, we provide comprehensive medical services and online retail pharmacy services through the Jianke Platform. Our comprehensive healthcare services include follow-up doctor consultation and electronic prescription services by registered physicians and in-house healthcare professionals through our innovative H2H (Hospital to Home) service platform. We also provide online retail pharmacy services to directly provide customers with a wide range of pharmaceuticals and health products. Our comprehensive medical services and online retail pharmacy services are supported by our Chronic Disease Management Service Center and a strong pharmaceutical supply chain. Furthermore, our platform's large and active user base enables us to effectively connect and interact with doctors and patients to provide them with targeted medical knowledge and content. With this powerful network effect, our platform provides pharmaceutical companies with customized content and sales management solutions to better inform doctors and patients about chronic disease conditions and treatment plans, and raise public awareness about diseases. As of December 31, 2023, the company's chronic disease management service platform had about 42.7 million registered users. For the year ended December 31, 2023, our fitness platform had an average of about 8.4 million monthly active users, and the number of registered doctors on our H2H platform reached 212,892. As of December 31, 2023, our registered physicians worked in more than 15,600 medical institutions, of which about 58.8% worked in level-III hospitals, and about 38.4% had obtained the title of Deputy Chief Physician or above. In the future, relying on our chronic disease management platform, we are committed to providing customized medical care and precision medicine for the growing number of patients with chronic diseases, with the goal of promoting services to a wider range of diseases.